Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline

Executive Summary

Antibiotic resistance has become a key market opportunity, but Big Pharma is poorly positioned to take advantage. Having all but abandoned antibiotic drug development at least a decade ago to smaller companies able to take on the risk, major drugmakers now look to those firms as a resource to revive their pipelines. But there may not be much to choose from.
Advertisement

Related Content

FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development
Tetraphase's Broad-Spectrum Antibiotic Candidate Makes A Good Showing At ICAAC
Dealmaking When Pharma's the Only Game in Town
Dealmaking When Pharma's the Only Game in Town
UK Antibiotics Play Novacta Wins £13.1 million, mostly from Celtic Pharma

Topics

Advertisement
UsernamePublicRestriction

Register

PS052642

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel